Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Increase in Short Interest

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 1,033,317 shares, an increase of 164.3% from the November 30th total of 391,017 shares. Currently, 6.1% of the company’s shares are short sold. Based on an average daily volume of 1,417,553 shares, the short-interest ratio is presently 0.7 days. Based on an average daily volume of 1,417,553 shares, the short-interest ratio is presently 0.7 days. Currently, 6.1% of the company’s shares are short sold.

Aptevo Therapeutics Stock Down 8.4%

NASDAQ APVO opened at $0.93 on Friday. Aptevo Therapeutics has a 52 week low of $0.91 and a 52 week high of $109.80. The business has a 50 day moving average price of $1.32 and a 200-day moving average price of $2.05. The company has a market cap of $15.74 million, a price-to-earnings ratio of -0.01 and a beta of 1.41.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.09) by ($0.14). On average, equities research analysts anticipate that Aptevo Therapeutics will post -15.84 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC bought a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned approximately 1.16% of Aptevo Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (e)” rating on shares of Aptevo Therapeutics in a research note on Monday. Zacks Research raised shares of Aptevo Therapeutics to a “hold” rating in a research report on Thursday, September 18th. Finally, Roth Capital upgraded Aptevo Therapeutics to a “strong-buy” rating in a report on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Aptevo Therapeutics has a consensus rating of “Hold”.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.